This trial is designed to see if the drug fremanezumab is effective in preventing migraines. It will last up to 36 months and will compare the drug to a placebo.
1 Primary · 12 Secondary · Reporting Duration: Baseline, Month 1, and Month 3
Experimental Treatment
Non-Treatment Group
288 Total Participants · 2 Treatment Groups
Primary Treatment: Fremanezumab · Has Placebo Group · Phase 3
Age 6 - 17 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Virginia | 50.0% |
California | 25.0% |
Tennessee | 25.0% |
18 - 65 | 100.0% |
Teva Investigational Site 14325 | 50.0% |
Teva Investigational Site 14374 | 50.0% |
Met criteria | 50.0% |
Did not meet criteria | 50.0% |